JLJacqueline A. Lees

Jacqueline A. Lees

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacqueline A. Lees has a total of 265 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PRMT5 inhibition disrupts detained intron splicing and impairs ATR signaling with increased DNA damage

    by Camille H. Cushman, Colin E. Fowler, Chiara Mazziotta, Mona M. Ahmed, Ziad Bakouny, Joao A. Paulo, Hembly G. Rivas, Jacqueline A. Lees, James A. DeCaprio, Jingwei Cheng

    PRMT5 catalyzes symmetric dimethyl arginine on numerous proteins, with PRMT5 inhibitors (PRMT5i) inducing anti-proliferative effects in preclinical studies. Several models have been proposed to explain sensitivity to PRMT5i including through p53 activation and DNA damage response (DDR) regulation. Here, we interrogate the mechanisms of PRMT5i sensitivity in Merkel cell carcinoma, a neuroendocrine skin cancer sensitive to p53 activation. To identify critical pathways altered by PRMT5i, we performed CRISPR/Cas9 screening, proteomic, and transcriptomic analyses. Our results indicate that PRMT5i sensitivity is independent of p53 activation and is characterized by an increase in detained introns (DIs) and dependency on mRNA processing factors. Sensitivity correlated with elevated basal DI levels and was associated with replication-associated DNA damage accompanied by impaired ATR/CHK1 signaling. These findings are consistent with a threshold model of sensitivity in which excessive DI accumulation is associated with replication-associated DNA damage and apoptosis following PRMT5 inhibition.


  • Open Access

    PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma

    by Colin E. Fowler, Natalie A. O’hEarn, Nicole Henning, Anthony Griffen, Nicolas Mathey-Andrews, Griffin J. Salus, Renin Hazan, Tyler Jacks, Aurora A. Burds, Helen S. Mueller, et al.

    Epigenetic changes are a major driver of cancer progression, placing considerable focus on epigenetic regulators as therapeutic targets. Protein arginine methyltransferase 5 (PRMT5) is one such regulator, and numerous PRMT5 inhibitors (PRMT5i) in clinical trials. Despite this, the mechanisms and consequences of PRMT5i-resistance are unknown. Here, we demonstrate that aggressive cancer progression is an inbuilt feature of PRMT5i-resistance acquisition in lung adenocarcinoma (LUAD). Independently-generated resistant cell lines gain dedifferentiation signatures that typify late-stage disease and show increased metastatic potential in vivo . We establish that these state shifts are a direct consequence of PRMT5i action; treatment induces rapid and widespread chromatin rewiring, enabling derepression of late-stage disease states that are stably established in resistant cells. Notably, treatment of lung tumor-bearing mice drives rapid disease advancement without decreasing tumor burden, showing that drug-induced disease progression supersedes any benefits from PRMT5 inhibition in vivo . Furthermore, analyses of human cell lines and patient cohorts supports the notion of PRMT5 inhibition-mediated dedifferentiation. Collectively our data show that PRMT5i can actively promote self-resistance and disease progression in different tumor types. This raises serious concerns for the use of PRMT5i in patients, arguing that clinical studies should consider the possibility of drug-induced plasticity, resistance, and disease advancement.

  • Open Access

    EMT-ciliary signaling in quasi-mesenchymal-stem-like cells drives therapeutic resistance and is a druggable vulnerability in triple-negative breast cancer

    by Camille E Tessier, Jennifer Derrien, Aurore M M Dupuy, Thomas Pelé, Martin Moquet, Julie Roul, Elise Douillard, Camille El Harrif, Xavier Pinson, Matthieu Le Gallo, et al.

    Cancer therapeutic resistance is mediated, in part, by phenotypic heterogeneity and the plasticity of tumor cells, the latter being enabled by epithelial–mesenchymal transition (EMT). However, EMT in human cancer therapeutic response remains poorly understood. We developed patient-derived organoids (PDOs) from human triple-negative breast cancer (TNBC) and investigated their response to chemotherapy. We found that chemotherapy treatment kills the bulk of tumor cells in PDOs, but there is selective survival of malignant cells that had activated an EMT program, entered a quasi-mesenchymal, stem cell-like state and display primary cilia. We developed a family of small-molecule inhibitors of ciliogenesis and show that treatment with these inhibitors, or genetic ablation of primary cilia, is sufficient to suppress this chemoresistance via NFκB-induced cell death. We conclude that an EMT–ciliary signaling axis induces chemoresistance in quasi-mesenchymal ciliated stem-like cells to help tumors evade chemotherapy and represents a druggable vulnerability in human TNBC.


  • Open Access

    The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing

    by Colin E. Fowler, Natalie A. O’HEarn, Griffin J. Salus, Arundeep Singh, Paul L. Boutz, Jacqueline A. Lees


  • Open Access

    The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing

    by Colin E. Fowler, Natalie A. O’hearn, Griffin J. Salus, Arundeep Singh, Paul L. Boutz, Jacqueline A. Lees

    Summary: Protein arginine methyltransferase 5 (PRMT5) is a promising cancer target, yet it’s unclear which PRMT5 roles underlie this vulnerability. Here, we establish that PRMT5 inhibition induces a special class of unspliced introns, called detained introns (DIs). To interrogate the impact of DIs, we depleted CLNS1A, a PRMT5 cofactor that specifically enables Sm protein methylation. We found that many, but not all, cell lines are CLNS1A-dependent and established that loss of viability is linked to loss of Sm protein methylation and DI upregulation. Finally, we discovered that PRMT5-regulated DIs, and the impacted genes, are highly conserved across human, and also mouse, cell lines but display little interspecies conservation. Despite this, human and mouse DIs have convergent impacts on proliferation by affecting essential components of proliferation-regulating complexes. Together, these data argue that the PRMT5-splicing axis, including appropriate DI splicing, underlies cancer’s vulnerability to PRMT5 inhibitors.


  • Open Access

    BMI1 is required for melanocyte stem cell maintenance and hair pigmentation

    by Molly M. Wilson, Paul S. Danielian, Griffin Salus, Roberta Ferretti, Charles A. Whittaker, Jacqueline A. Lees

    The epigenetic repressor BMI1 plays an integral role in promoting the self‐renewal and proliferation of many adult stem cell populations, and also tumor types, primarily through silencing the Cdkn2a locus, which encodes the tumor suppressors p16Ink4a and p19Arf. However, in cutaneous melanoma, BMI1 drives epithelial‐mesenchymal transition programs, and thus metastasis, while having little impact on proliferation or primary tumor growth. This raised questions about the requirement and role for BMI1 in melanocyte stem cell (McSC) biology. Here, we demonstrate that murine melanocyte‐specific Bmi1 deletion causes premature hair greying and gradual loss of melanocyte lineage cells. Depilation enhances this hair greying defect, accelerating depletion of McSCs in early hair cycles, suggesting that BMI1 acts to protect McSCs against stress. RNA‐seq of McSCs, harvested before onset of detectable phenotypic defects, revealed that Bmi1 deletion derepresses p16Ink4a and p19Arf, as observed in many other stem cell contexts. Additionally, BMI1 loss downregulated the glutathione S‐transferase enzymes, Gsta1 and Gsta2, which can suppress oxidative stress. Accordingly, treatment with the antioxidant N‐acetyl cysteine (NAC) partially rescued melanocyte expansion. Together, our data establish a critical function for BMI1 in McSC maintenance that reflects a partial role for suppression of oxidative stress, and likely transcriptional repression of Cdkn2a.


  • Open Access

    Supplementary Figures S1-S2 from The Retinoblastoma Protein Tumor Suppressor Is Important for Appropriate Osteoblast Differentiation and Bone Development

    by Seth D. Berman, Tina L. Yuan, Emily S. Miller, Eunice Y. Lee, Alicia Caron, Jacqueline A. Lees

    Supplementary Figures S1-S2 from The Retinoblastoma Protein Tumor Suppressor Is Important for Appropriate Osteoblast Differentiation and Bone Development

  • Open Access

    MITF deficiency and oncogenic GNAQ each promote proliferation programs in zebrafish melanocyte lineage cells

    by Grace B. Phelps, Adam Amsterdam, Hannah R. Hagen, Nicole Zambrana García, Jacqueline A. Lees

    Uveal melanoma (UM) is the most common primary malignancy of the adult eye but lacks any FDA‐approved therapy for the deadly metastatic disease. Thus, there is a great need to dissect the driving mechanisms for UM and develop strategies to evaluate potential therapeutics. Using an autochthonous zebrafish model, we previously identified MITF, the master melanocyte transcription factor, as a tumor suppressor in GNAQQ209L‐driven UM. Here, we show that zebrafish mitfa‐deficient GNAQQ209L‐driven tumors significantly up‐regulate neural crest markers, and that higher expression of a melanoma‐associated neural crest signature correlates with poor UM patient survival. We further determined how the mitfa‐null state, as well as expression of GNAQQ209L, YAPS127A;S381A, or BRAFV600E oncogenes, impacts melanocyte lineage cells before they acquire the transformed state. Specifically, examination 5 days post‐fertilization showed that mitfa‐deficiency is sufficient to up‐regulate pigment progenitor and neural crest markers, while GNAQQ209L expression promotes a proliferative phenotype that is further enhanced by YAPS127A;S381A co‐expression. Finally, we show that this oncogene‐induced proliferative phenotype can be used to screen chemical inhibitors for their efficacy against the UM pathway. Overall, this study establishes that a neural crest signature correlates with poor UM survival, and describes an in vivo assay for preclinical trials of potential UM therapeutics.


  • Open Access

    MITF deficiency accelerates GNAQ-driven uveal melanoma

    by Grace B. Phelps, Hannah R. Hagen, Adam Amsterdam, Jacqueline A. Lees

    Significance: Uveal melanoma (UM) is a cancer of eye melanocytes. Although relatively rare, UM is extremely deadly, as approximately half of all patients develop liver metastases for which there are no approved therapies. Even therapies that succeed in cutaneous melanoma (CM) treatment have proven ineffectual for UM, highlighting both the distinct nature of these two melanomas and the need to understand the differences between them. Here, we show that autochthonous UM tumors are rapidly induced by activated YAP and can lack hyperactive ERK, highlighting YAP as a promising therapeutic target. We further show thatMITFfunctions as a tumor suppressor in UM in contrast to its essential role in CM, establishing that MITF inhibition should not be entertained for UM treatment.


  • Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis

    by Yun Zhang, Joana Liu Donaher, Sunny Das, Xin Li, Ferenc Reinhardt, Jordan A. Krall, Arthur W. Lambert, Prathapan Thiru, Heather R. Keys, Mehreen Khan, et al.

    Epithelial–mesenchymal transition (EMT) programs operate within carcinoma cells, where they generate phenotypes associated with malignant progression. In their various manifestations, EMT programs enable epithelial cells to enter into a series of intermediate states arrayed along the E–M phenotypic spectrum. At present, we lack a coherent understanding of how carcinoma cells control their entrance into and continued residence in these various states, and which of these states favour the process of metastasis. Here we characterize a layer of EMT-regulating machinery that governs E–M plasticity (EMP). This machinery consists of two chromatin-modifying complexes, PRC2 and KMT2D-COMPASS, which operate as critical regulators to maintain a stable epithelial state. Interestingly, loss of these two complexes unlocks two distinct EMT trajectories. Dysfunction of PRC2, but not KMT2D-COMPASS, yields a quasi-mesenchymal state that is associated with highly metastatic capabilities and poor survival of patients with breast cancer, suggesting that great caution should be applied when PRC2 inhibitors are evaluated clinically in certain patient cohorts. These observations identify epigenetic factors that regulate EMP, determine specific intermediate EMT states and, as a direct consequence, govern the metastatic ability of carcinoma cells.